Volume 25, Issue 6, Pages (June 2017)

Slides:



Advertisements
Similar presentations
Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.
Advertisements

Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis  Dariush Haghmorad, Mohammad Bagher.
Volume 23, Issue 5, Pages (May 2015)
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β- Defensins via Induction of Regulatory T Cells  Anika Bruhs, Thomas.
AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells by Federico Mingozzi, Janneke.
Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis  Dao X. Nguyen, BSc, Alice Cotton, RN, BSc, Laura Attipoe, MBBS, Coziana.
Reduced Frequency of Regulatory T Cells in Peripheral Blood Stem Cell Compared to Bone Marrow Transplantations  Céline Blache, Joe-Marc Chauvin, Aude.
Volume 25, Issue 10, Pages (October 2017)
CD56+/CD16− Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis  P.
Volume 76, Issue 7, Pages (October 2009)
Molecular Therapy - Methods & Clinical Development
In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial  Divya T. Koura, John T.
Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products by David-Alexandre.
Inflammation Promotes the Loss of Adeno-Associated Virus–Mediated Transgene Expression in Mouse Liver  Ekaterina Breous, Suryanarayan Somanathan, Peter.
Molecular Therapy - Methods & Clinical Development
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation 
Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma  Kenneth R. Meehan, Laleh Talebian,
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
Volume 19, Issue 2, Pages (February 2011)
CD56+/CD16− Natural Killer cells expressing the inflammatory protease granzyme A are enriched in synovial fluid from patients with osteoarthritis  P.
Volume 9, Issue 3, Pages (March 2004)
Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated Liposomes  Adam Judge, Kevin McClintock, Janet R. Phelps,
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Methods & Clinical Development
Volume 25, Issue 3, Pages (March 2017)
Forkhead box protein 3 demethylation is associated with tolerance induction in peanut- induced intestinal allergy  Meiqin Wang, MD, PhD, Ivana V. Yang,
Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma  Thomas Schneider,
Volume 25, Issue 6, Pages (June 2017)
Volume 19, Issue 3, Pages (March 2011)
Katherine G. MacDonald, BSc, Nicholas A. J
Volume 19, Issue 11, Pages (November 2011)
Volume 18, Issue 6, Pages (June 2010)
Volume 23, Issue 10, Pages (October 2015)
Volume 19, Issue 2, Pages (February 2011)
Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques  Juliette Hordeaux, Christian Hinderer,
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Volume 26, Issue 4, Pages (April 2018)
Volume 26, Issue 1, Pages (January 2018)
Volume 22, Issue 1, Pages (January 2014)
Volume 25, Issue 4, Pages (April 2017)
Volume 18, Issue 1, Pages (January 2010)
Volume 14, Issue 2, Pages (February 2001)
Volume 18, Issue 1, Pages (January 2010)
Volume 18, Issue 10, Pages (October 2010)
Volume 17, Issue 2, Pages (February 2009)
Volume 18, Issue 7, Pages (July 2010)
Hypersensitivity and Loss of Disease Site Targeting Caused by Antibody Responses to PEGylated Liposomes  Adam Judge, Kevin McClintock, Janet R. Phelps,
In Vivo Expansion of Regulatory T cells With IL-2/IL-2 mAb Complexes Prevents Anti- factor VIII Immune Responses in Hemophilia A Mice Treated With Factor.
Volume 12, Issue 5, Pages (November 2005)
Volume 25, Issue 11, Pages (November 2017)
Volume 20, Issue 3, Pages (March 2012)
Volume 28, Issue 5, Pages (May 2008)
Volume 18, Issue 6, Pages (June 2010)
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Volume 25, Issue 4, Pages (April 2017)
Volume 26, Issue 4, Pages (April 2018)
Volume 23, Issue 1, Pages (January 2015)
Volume 27, Issue 7, Pages (July 2019)
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Oncolytics
Volume 17, Issue 11, Pages (November 2009)
Volume 25, Issue 6, Pages (June 2017)
Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.
Volume 3, Issue 5, Pages (May 2001)
Immunologic and pharmacokinetic studies.
Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.
Volume 23, Issue 5, Pages (May 2015)
Volume 27, Issue 5, Pages (May 2019)
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Volume 25, Issue 6, Pages 1387-1394 (June 2017) 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency  Christian Mueller, Gwladys Gernoux, Alisha M. Gruntman, Florie Borel, Emer P. Reeves, Roberto Calcedo, Farshid N. Rouhani, Anthony Yachnis, Margaret Humphries, Martha Campbell-Thompson, Louis Messina, Jeffrey D. Chulay, Bruce Trapnell, James M. Wilson, Noel G. McElvaney, Terence R. Flotte  Molecular Therapy  Volume 25, Issue 6, Pages 1387-1394 (June 2017) DOI: 10.1016/j.ymthe.2017.03.029 Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 M-AAT Serum Levels over the 5 Years after Intramuscular Administration of rAAV1-CB-hAAT The dotted line is at ∼2.5% of the target therapeutic serum concentration of 572 μg/mL (11 μM). The serum AAT levels were assayed using a M-AAT-specific ELISA. The high dose was 6.0 × 1012 vg/kg, the mid dose was 1.9 × 1012 vg/kg, and the low dose was 6.0 × 1011 vg/kg. Early time points previously reported in Mueller et al.18 Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 M-AAT Expression in Skeletal Muscle 3 Months, 12 Months, and 5 Years after Intramuscular Administration of rAAV1-CB-hAAT Muscle immunochemistry staining for hAAT. The specimens were biopsied from the area injected with rAAV1 and the tissue stained for hAAT (brown). The AAT expression was persistent, while inflammatory cell infiltrates decreased over time from 3 months to 5 years. All of the slides are from patient 308. (A) Tissue 3 months after rAAV1-CB-hAAT delivery. (B) Tissue 12 months after rAAV1-CB-hAAT delivery. (C and D) Tissue 5 years after rAAV1-CB-hAAT delivery. Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 3 Immunophenotyping of Cellular Infiltrates in Skeletal Muscle at the Injection Site 5 Years after Intramuscular Administration of rAAV1-CB-hAAT (A) hAAT immunohistochemistry showing microfoci of immune cells around cell expression hAAT. (B) CD3 staining, demonstrating that many of the mononuclear immune cells are T-lymphocytes. (C) CD8 staining indicating a population of cytotoxic T cells. (D) CD68 staining indicating a population of macrophages. (E) CD20 staining indicating a small population of B-lymphocytes. Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 4 Bisulfite Sequencing to Quantify the Percentage of Immune Cells in Muscle Biopsies Obtained 5 Years after Intramuscular Administration of rAAV1-CB-hAAT A relatively high proportion of Tregs was observed in the muscle immune cell population. (A) Percentage of CD3+, Treg (FOXP3+), and CD8+ cells in the muscle. (B) Treg and CD8+ cells as a percentage of CD3+ cell population in the muscle. Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 5 Regulatory T Cell and Exhausted T Cell Detection by Flow Cytometry in Samples from Muscle Biopsies Obtained 5 Years after Intramuscular Administration of rAAV1-CB-hAAT (A) Regulatory T cells were gated as Helios+FoxP3+ cells in the CD3+CD4+ subset. The activated Treg cells were defined as OX40+CD25+ cells. (B) Exhausted CD8 T cells were gated as LAG-3+PD-1+ cells in the CD3+CD8+ subset. The percentages of each population are indicated in the dot plots. Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 6 Peripheral Gamma-IFN ELISPOT Responses to AAV Capsid Epitope Pools A decreased peripheral blood AAV1 reactivity was observed at month 52 compared to earlier time points (all of the data from patient 308). SFU, spot forming units; PBMC, peripheral blood mononuclear cell; AAV1a/b/c, pools of AAV1 peptides; CEF, positive control peptide pool. Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 7 Elastase Inhibitory Activity Assay Inhibition of neutrophil elastase was quantified by a colorimetric assay in triplicates and reported as % of no inhibitor control ±SEM. The patients were dosed with rAAV1-AAT gene therapy treatment at day 0 and serum was sampled pretreatment and at 3 months, 1 year, and 5 years post treatment. Patients 306 and 307 started protein augmentation therapy (Protein Rx) after their 1 year follow up. Additional controls included two PiM (MM) individuals and two PiZ (ZZ) individuals under protein augmentation therapy (PiZ Protein Rx) (500 nM Elastinal indicates the elastase activity control). Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions

Figure 8 Biomarkers of Degranulation and Auto-Antibodies: TNF-R1 and Neutrophil Anti-Lactoferrin TNF-R1 levels in patients treated with gene therapy approached that of control PiM patients (M-AAT/MM). Anti-lactoferrin staining indicated that the rAAV1-AAT treated patient had an approximately 50% correction in this marker. (A) TNFR1 levels in the serum 5 years post-gene delivery. The patient 306 serum data were collected following lung transplant and subsequent pulmonary Aspergillosis diagnosis. (B) Anti-lactoferrin levels in PFA fixed neutrophils (AAT Day 2: Day 2 after protein replacement therapy in a PiZ [ZZ] patient). Molecular Therapy 2017 25, 1387-1394DOI: (10.1016/j.ymthe.2017.03.029) Copyright © 2017 The Author(s) Terms and Conditions